Drug Detail

Drug Name LY3214996
Trade Name
Drug Descriptions

LY3214996 inhibits ERK1/2, potentially resulting in decreased growth of tumors with alterations in the RAS/MAPK pathway (AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4973).

DrugClasses ERK Inhibitor (pan) 14


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Abemaciclib + LY3214996 Abemaciclib LY3214996 0 1
Gemcitabine + LY3214996 + Nab-paclitaxel Gemcitabine LY3214996 Nab-paclitaxel 0 1
LSN3074753 + LY3214996 LSN3074753 LY3214996 0 0
LY3009120 + LY3214996 LY3009120 LY3214996 0 0
LY3214996 LY3214996 0 1
LY3214996 + Midazolam LY3214996 Midazolam 0 1

Additional content available in CKB BOOST